Resource Summary Report

Generated by FDI Lab - SciCrunch.org on May 28, 2025

Brilliant Violet 711(TM) anti-T-bet

RRID:AB_2715766 Type: Antibody

Proper Citation

(BioLegend Cat# 644820, RRID:AB_2715766)

Antibody Information

URL: http://antibodyregistry.org/AB_2715766

Proper Citation: (BioLegend Cat# 644820, RRID:AB_2715766)

Target Antigen: T-bet

Host Organism: mouse

Clonality: monoclonal

Comments: Applications: ICFC

Antibody Name: Brilliant Violet 711(TM) anti-T-bet

Description: This monoclonal targets T-bet

Target Organism: Human, Mouse

Clone ID: Clone 4B10

Antibody ID: AB_2715766

Vendor: BioLegend

Catalog Number: 644820

Alternative Catalog Numbers: 644819

Record Creation Time: 20231110T033810+0000

Record Last Update: 20240725T000839+0000

Ratings and Alerts

No rating or validation information has been found for Brilliant Violet 711(TM) anti-T-bet.

No alerts have been found for Brilliant Violet 711(TM) anti-T-bet.

Data and Source Information

Source: Antibody Registry

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at FDI Lab - SciCrunch.org.

van Elsas MJ, et al. (2024) Immunotherapy-activated T cells recruit and skew late-stage activated M1-like macrophages that are critical for therapeutic efficacy. Cancer cell, 42(6), 1032.

Padoan B, et al. (2024) NKp44/HLA-DP-dependent regulation of CD8 effector T cells by NK cells. Cell reports, 43(4), 114089.

Nuñez NG, et al. (2023) Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. Med (New York, N.Y.), 4(2), 113.

van Elsas MJ, et al. (2023) Invasive margin tissue-resident macrophages of high CD163 expression impede responses to T cell-based immunotherapy. Journal for immunotherapy of cancer, 11(3).

Venturutti L, et al. (2023) An Aged/Autoimmune B-cell Program Defines the Early Transformation of Extranodal Lymphomas. Cancer discovery, 13(1), 216.

Lu YJ, et al. (2021) CD4 T cell help prevents CD8 T cell exhaustion and promotes control of Mycobacterium tuberculosis infection. Cell reports, 36(11), 109696.

Passaes C, et al. (2020) Optimal Maturation of the SIV-Specific CD8+ T Cell Response after Primary Infection Is Associated with Natural Control of SIV: ANRS SIC Study. Cell reports, 32(12), 108174.